Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study)

PURPOSE: Hyperkalemia is a common metabolic complication of chronic kidney disease (CKD) and is associated with several serious adverse events. We aimed to treat/prevent hyperkalemia using the new of potassium-binders, allowing maintained renin-angiotensin-aldosterone system inhibitors (RAASi) treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjune, Thea, Bøe, Thea Bjerkestrand, Kjellevold, Stig Arne, Heldal, Kristian, Abedini, Sadollah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027611/
https://www.ncbi.nlm.nih.gov/pubmed/36960344
http://dx.doi.org/10.2147/IJNRD.S401623
_version_ 1784909741501186048
author Bjune, Thea
Bøe, Thea Bjerkestrand
Kjellevold, Stig Arne
Heldal, Kristian
Abedini, Sadollah
author_facet Bjune, Thea
Bøe, Thea Bjerkestrand
Kjellevold, Stig Arne
Heldal, Kristian
Abedini, Sadollah
author_sort Bjune, Thea
collection PubMed
description PURPOSE: Hyperkalemia is a common metabolic complication of chronic kidney disease (CKD) and is associated with several serious adverse events. We aimed to treat/prevent hyperkalemia using the new of potassium-binders, allowing maintained renin-angiotensin-aldosterone system inhibitors (RAASi) treatment in proteinuric CKD and/or congestive heart failure (CHF) patients. PATIENTS AND METHODS: We conducted a retrospective cohort study in long-term users of potassium binders for chronic hyperkalemia. Patients aged 18 years and older, treated with potassium-binders and who met the reimbursement criteria and indication for RAASi treatment were included. RESULTS: Fifty-seven percent of the patients were males and mean age was 65 years. During the study period, no patients were admitted to hospital due to hyperkalemia after initiation of potassium binders. Potassium maximum values were significantly lower after treatment. Few patients reported major side effects, and discontinuation was mostly due to normokalemia. We found no significant changes in bicarbonate, serum creatinine or GFR stage after starting potassium binder treatment. All patients on RAASi treatment before initiating potassium-binders were retained on RAASi treatment. CONCLUSION: New potassium binders in clinical practice are an easy and safe treatment with few side effects and good tolerance, that significantly lowers the risk of hyperkalemia. Furthermore, and most importantly, patients can be maintained on RAASi treatment.
format Online
Article
Text
id pubmed-10027611
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-100276112023-03-22 Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study) Bjune, Thea Bøe, Thea Bjerkestrand Kjellevold, Stig Arne Heldal, Kristian Abedini, Sadollah Int J Nephrol Renovasc Dis Original Research PURPOSE: Hyperkalemia is a common metabolic complication of chronic kidney disease (CKD) and is associated with several serious adverse events. We aimed to treat/prevent hyperkalemia using the new of potassium-binders, allowing maintained renin-angiotensin-aldosterone system inhibitors (RAASi) treatment in proteinuric CKD and/or congestive heart failure (CHF) patients. PATIENTS AND METHODS: We conducted a retrospective cohort study in long-term users of potassium binders for chronic hyperkalemia. Patients aged 18 years and older, treated with potassium-binders and who met the reimbursement criteria and indication for RAASi treatment were included. RESULTS: Fifty-seven percent of the patients were males and mean age was 65 years. During the study period, no patients were admitted to hospital due to hyperkalemia after initiation of potassium binders. Potassium maximum values were significantly lower after treatment. Few patients reported major side effects, and discontinuation was mostly due to normokalemia. We found no significant changes in bicarbonate, serum creatinine or GFR stage after starting potassium binder treatment. All patients on RAASi treatment before initiating potassium-binders were retained on RAASi treatment. CONCLUSION: New potassium binders in clinical practice are an easy and safe treatment with few side effects and good tolerance, that significantly lowers the risk of hyperkalemia. Furthermore, and most importantly, patients can be maintained on RAASi treatment. Dove 2023-03-16 /pmc/articles/PMC10027611/ /pubmed/36960344 http://dx.doi.org/10.2147/IJNRD.S401623 Text en © 2023 Bjune et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Bjune, Thea
Bøe, Thea Bjerkestrand
Kjellevold, Stig Arne
Heldal, Kristian
Abedini, Sadollah
Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study)
title Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study)
title_full Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study)
title_fullStr Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study)
title_full_unstemmed Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study)
title_short Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study)
title_sort hyperkalemia and the use of new potassium binders a single center experience from vestfold norway (the potbind study)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027611/
https://www.ncbi.nlm.nih.gov/pubmed/36960344
http://dx.doi.org/10.2147/IJNRD.S401623
work_keys_str_mv AT bjunethea hyperkalemiaandtheuseofnewpotassiumbindersasinglecenterexperiencefromvestfoldnorwaythepotbindstudy
AT bøetheabjerkestrand hyperkalemiaandtheuseofnewpotassiumbindersasinglecenterexperiencefromvestfoldnorwaythepotbindstudy
AT kjellevoldstigarne hyperkalemiaandtheuseofnewpotassiumbindersasinglecenterexperiencefromvestfoldnorwaythepotbindstudy
AT heldalkristian hyperkalemiaandtheuseofnewpotassiumbindersasinglecenterexperiencefromvestfoldnorwaythepotbindstudy
AT abedinisadollah hyperkalemiaandtheuseofnewpotassiumbindersasinglecenterexperiencefromvestfoldnorwaythepotbindstudy